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Abstract
Mutations in the sarcomeric protein titin, encoded by TTN, are emerging as a common cause of myopathies. The diagnosis 
of a TTN-related myopathy is, however, often not straightforward due to clinico-pathological overlap with other myopathies 
and the prevalence of TTN variants in control populations. Here, we present a combined clinico-pathological, genetic and 
biophysical approach to the diagnosis of TTN-related myopathies and the pathogenicity ascertainment of TTN missense 
variants. We identified 30 patients with a primary TTN-related congenital myopathy (CM) and two truncating variants, or 
one truncating and one missense TTN variant, or homozygous for one TTN missense variant. We found that TTN-related 
myopathies show considerable overlap with other myopathies but are strongly suggested by a combination of certain clinico-
pathological features. Presentation was typically at birth with the clinical course characterized by variable progression 
of weakness, contractures, scoliosis and respiratory symptoms but sparing of extraocular muscles. Cardiac involvement 
depended on the variant position. Our biophysical analyses demonstrated that missense mutations associated with CMs are 
strongly destabilizing and exert their effect when expressed on a truncating background or in homozygosity. We hypothesise 
that destabilizing TTN missense mutations phenocopy truncating variants and are a key pathogenic feature of recessive 
titinopathies that might be amenable to therapeutic intervention.
Introduction
The giant muscle protein titin (also known as connectin) acts 
as an essential architectural integrator of striated muscle sar-
comeres in heart and skeletal muscle by directing the exact 
subsarcomeric positions of hundreds of other sarcomeric 
proteins [14, 28]. Titin is a protein of over 1 µm in length, 
with a molecular weight in excess of 3 MDa, and is encoded 
by the TTN gene, which assembles the primary ~ 100 kb 
transcript from 364 exons in a 300 kb gene [2, 8]. The pro-
tein contains 132 fibronectin-3 (Fn3) domains, one kinase 
domain and up to 169 immunoglobulin (Ig) domains, and 
unstructured regions [29]. In addition to its architectural and 
mechanical functions in assembling sarcomeres and support-
ing their contraction and relaxation, the C-terminal, M-band 
region of titin has emerged as a hub for the coordination of 
sarcomere proteostasis [33].
Recently, mutations in TTN have emerged as a major 
cause of both dominantly and recessively inherited myo-
pathies covering a wide and still expanding spectrum (for 
review [8, 53]), including tibial muscular dystrophy (TMD) 
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[21], limb girdle muscular dystrophy 2 J (LGMD2J) [21], 
hereditary myopathy with early respiratory failure (HMERF) 
[23, 24, 33, 38, 41, 57], Salih myopathy [4], centronuclear 
myopathy (CNM) [6], core myopathy with heart disease 
[7] and childhood-juvenile onset Emery-Dreifuss-like phe-
notype without cardiomyopathy [10]. There is emerging 
evidence that many of these presentations form part of a 
continuum of “congenital titinopathy” [40] rather than dis-
tinct entities. TTN-related myopathies show considerable 
clinico-pathological overlap as a group but also with other 
neuromuscular disorders, in particular the congenital myo-
pathies (CMs), limb girdle muscular dystrophies (LGMDs) 
and distal myopathies. TTN mutations, whether recessive 
or dominant, are also emerging as major causes of dilated 
cardiomyopathy [3, 18, 43, 59, 60] and have been implicated 
in hypertrophic cardiomyopathy (HCM) [35], however no 
families with co-segregation of TTN missense variants with 
HCM or DCM have been identified to date [1, 56].
An intriguing feature of titinopathies is their often highly 
restricted disease manifestation, even for missense variants 
in domains ubiquitously expressed in striated muscle. For 
example, dominantly-inherited TMD [21] involves almost 
exclusively the tibialis anterior muscle, despite the TTN 
mutation affecting the ubiquitous interaction between 
obscurin and titin [12, 44, 45]. Even patients with reces-
sively inherited LGMD2J due to homozygosity for the same 
TTN mutation, despite a more extensive skeletal-muscle phe-
notype, do not normally develop a cardiomyopathy. Also, 
mutations in the fibronectin (Fn3)-119 domain, which 
is expressed in all TTN transcripts, are the main cause of 
HMERF [48, 53]. Cardiac involvement is not a consistent 
feature of HMERF, although recent studies reveal that some 
patients may develop conduction abnormalities [55].
To date, around 130 pathogenic TTN coding sequence 
mutations have been reported in association with skeletal 
and/or cardiac myopathies (for review [8, 53]), the majority 
truncating loss-of-function mutations (TTNtv). Recessive 
truncating mutations near the C-terminal M-band have been 
identified as the cause of Salih myopathy [4], whereas more 
recently identified recessive mutations in CNM with variable 
cardiac involvement [6] and other neuromuscular phenotypes 
also involve the N-terminal region, and comprise compound 
heterozygosity of either two truncating mutations or a trun-
cation and missense mutation in trans [7, 41]. While there 
is emerging understanding of the functional consequences 
of TTNtv, the mechanistic impact of most missense variants 
and their interplay in compound-heterozygous inheritance 
with truncating variants is still unclear, resulting in patients 
with potentially pathogenic TTN variants where no definite 
diagnostic conclusion can be reached due to limitations of 
pathogenicity ascertainment.
Correct interpretation of TTN variants identified in 
patients presenting with neuromuscular features poses 
several challenges, mainly reflecting the giant size of the 
TTN gene and the substantial associated spontaneous genetic 
variation even in healthy individuals. Presence of a TTN 
variant on databases of genetic variation does not neces-
sarily preclude its pathogenicity, as demonstrated for the 
recessive titin kinase (TK) domain variant Trp260Arg 
(p.Trp34072Arg using the inferred complete, IC, nomen-
clature) [7], which, like almost 20 other TK domain variants 
predicted to be disruptive, is found on the 1000 genomes 
and other genomic variation databases [17, 34]. Vice versa, 
absence of a TTN variant in large control populations does 
not necessarily support its pathogenicity, as demonstrated 
by very rare, often private TTN missense variants that are 
not always predicted to be disruptive [29]. The pathogenic-
ity of TTNtv is supported by their implication in human 
disease phenotypes such as the primary dilated cardiomy-
opathies and their relative low frequency on databases of 
human genetic variation. However, truncating TTN variants 
are carried by about 1:100 of the population [50, 54]. This 
is much higher than the incidence of DCM by all estab-
lished causes combined (about 1:500) and also higher than 
the estimated occurrence of TTNtv of about 1:1000 in end-
stage or familial DCM cases [11, 58]. TTNtv therefore may 
also be carried by entirely healthy individuals. Whilst not 
without pitfalls for truncating TTN variants, pathogenicity 
assessment is even more challenging for TTN missense vari-
ants, which account for 90% of TTN variants identified in 
a HCM cohort [35]. Moreover, in contrast to other neuro-
muscular disorders due to mutations affecting less complex 
proteins, in silico analysis of TTN variants is often severely 
limited and may even result in predictions conflicting with 
the results of a more rigorous functional analysis [7]. In 
addition, clinico-pathological features associated with TTN 
mutations are often insufficiently specific to predict TTN 
involvement confidently, potentially causing further confu-
sion, as the TTN variants identified in a specific patient may 
be coincidental to another Mendelian disorder with overlap-
ping clinico-pathological features. This may be particularly 
true for recessive missense variants, which are expected to 
occur in the population at a detectable frequency.
Missense mutations in titin M10 linked to LGMD2J and 
TMD have previously been biophysically characterised, 
with mutations deemed causative either preventing correct 
folding or thermally destabilising the domain by 21 °C, and 
preventing binding to its ligand Obscurin Ig-1 [52]. Simi-
larly, the impact of HMERF-linked mutations in Fn3-119 
have been attributed to misfolding of the domain, based on 
the inability of soluble mutant protein to be purified from 
E. coli [23, 24].
Due to the now-routine use of next generation sequenc-
ing in clinical diagnostics, it is likely that information 
regarding genetic variation in the TTN gene and the 
group of TTN-related myopathies will continue to expand 
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massively in the coming years, emphasizing the need for 
a structured approach to pathogenicity assessment and to 
establish reliable genotype–phenotype correlations. Here, 
we present a comprehensive approach to the assessment of 
(in particular missense) TTN variants in the context of sug-
gestive clinico-pathological features. We use an integrated 
biochemical and biophysical approach to assess the impact 
of titin missense variants on protein stability and highlight 
histopathological and clinical findings more suggestive of 
a TTN–related myopathy compared to other neuromuscular 
disorders presenting with overlapping features.
Methods
Patients
Patients with a clinico-pathological diagnosis of a CM and 
at least two truncating, splice-site or rare missense variants 
either in trans or with unknown inheritance in the TTN gene 
were recruited from the participating tertiary neuromuscular 
centres. Genetic data as well as clinical and pathological fea-
tures, including those considered to be suggestive of TTN-
related myopathies (as listed in Oates et al., Tables 1 and 2) 
[40] were systematically captured. All numbering of genetic 
Table 1  Key clinical and histopathological features of patients with TTN-related myopathies
F female, M male, A Alive, D Dead, Histo Histology, CNM Centronuclear Myopathy, CFTD Congenital Fibre Type Disproportion, MmD Multi-
minicore Disease, CM congenital myopathy with multiple or non-specific features, T1P Type 1 predominance, Cardiac cardiac involvement, 
CMP cardiomyopathy, Resp respiratory involvement, Vent Ventilation, Bulbar involvement
*Lost ambulation at 14 years of age
**Underwent cardiac transplant
Patient Sex Age A/D Histo Onset Function Contractures Scoliosis Surgery Cardiac CMP Resp Vent Bulbar
1 M 37 A CFTD Neonatal Sitting Yes Yes No No No Yes Tracheo No
2 F 30 A CNM Neonatal Walking Yes Yes ND Yes Yes Yes NIV Yes
3 M 12 A CNM Infancy Sitting Yes Yes No No No Yes NIV Yes
4 M 10w D CNM Neonatal NA No No NA No ND Yes NIV Yes
5 F 3 A CNM Antenatal Sitting Yes Yes No Yes Yes Yes Tracheo Yes
6 M 14 A MmD Infancy Walking No Yes ND No No No NA No
7 F 12 A MmD Childhood Walking No No ND No No Yes NA No
8 M 8 A CFTD Neonatal Walking No Yes No No No Yes NIV Yes
9 F 23 A CNM Childhood Walking Yes Yes No No No Yes NA No
10 M 19 A CNM Childhood Walking Yes Yes No No No Yes NA No
11 M 14 A CFTD Childhood Walking ND Yes Yes No No No NA No
12 M 16 A CFTD Antenatal Walking Yes Yes Yes No No Yes NIV No
13 M 11 A CM Infancy Walking Yes No NA No No Yes NA No
14 F 24 A CNM Neonatal Walking Yes Yes Yes Yes Yes Yes NIV Yes
15 M 21 A T1P Antenatal Walking Yes Yes Yes Yes Yes Yes NA Yes
16 F 13 A ND Antenatal Walking No Yes NA Yes Yes Yes NA No
17 M 19 A MmD Infancy Walking Yes No No No No Yes NIV No
18 M 71 A MmD Childhood Walking Yes Yes No Yes Yes Yes NA Yes
19 F 54 D ND Infancy Walking ND Yes No Yes Yes Yes NA ND
20 F 50 A MmD Neonatal Walking No Yes No Yes Yes No NA No
21 M 47 A MmD Neonatal Walking No ND ND Yes Yes Yes ND No
22 M 18 A MmD Neonatal Walking Yes Yes ND Yes Yes** No NA ND
23 M 3 m D CNM Antenatal NA ND ND NA ND ND Yes NIV Yes
24 M 9 A MmD Neonatal Walking No Yes Yes Yes Yes** Yes NIV No
25 M 31 A CM Infancy Walking* Yes Yes Yes No No Yes NIV No
26 F 25 A CM Infancy Walking No Yes No No No Yes NA No
27 F 27 A MmD Antenatal Walking (S) No ND ND Yes No Yes NA Yes
28 M 10 A CM Neonatal Walking (S) Yes Yes No Yes Yes Yes NIV Yes
29 M 32 A CNM Neonatal Walking Yes No NA Yes Yes Yes NA No
30 F 32 A CM Antenatal Walking Yes Yes Yes No No Yes NIV No

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































436 Acta Neuropathologica (2021) 141:431–453
1 3
variants corresponds to the IC transcript NM_001267550; 
LRG391_t1. 
Muscle biopsy
Muscle biopsies were performed as part of the routine diag-
nostic work-up. Histological, histochemical, immunohisto-
chemical stains and ultrastructural studies were performed 
according to standard protocols.
Muscle imaging
Muscle MRI, CT and/or US images mainly from the pelvis 
and the lower limbs were obtained from selected patients 
applying standard protocols.
Genetic studies
Sequencing of the TTN coding sequence was performed 
as part of the normal diagnostic process or through whole 
exome sequencing as part of a research study. Some details 
from Patient 22, who presented with the truncating mutation 
(p.Asn34020Thrfs*9) and Val22232Glu missense variant 
have been reported previously as Patient 4 in [7].
Bioinformatics
The impact of missense variants in the study cohort were 
predicted using various bioinformatic predictors. CONDEL 
[20], mCSM [49] and Q(SASA) values [5] and gnomAD 
minor allele frequencies [34] were retrieved from TITINdb 
[29]. CADD Phred scores for the missense variants in this 
study, alongside all Titin missense variants in the ClinVar 
[30] and GnomAD databases were retrieved from the CADD 
database [51].
Molecular cloning
For bacterial protein expression, DNA encoding titin 
domains Ig-1, Ig-33, Ig-87, Fn3-4, Fn3-7, Fn3-12, Fn3-
20, Fn3-49, Fn-69, Fn3-73, Fn3-90, Fn3-119 and Fn3-120 
were amplified from a human skeletal-muscle cDNA library 
and inserted into modified pET6His vectors. For domain 
boundaries see Supplementary Table 1. Missense variants 
Ala82Asp (Ig-1), Cys5054Arg (Ig-33), Ala13715Glu (Ig-
87), Asn16133Lys (Fn3-4), Trp16471Cys (Fn3-7), Cys-
17051Arg (Fn3-12), Leu18237Pro (Fn3-20), Val22232Glu 
(Fn3-49), Arg24947Cys (Fn3-69), Arg25480Pro (Fn3-73), 
Ile27775Val (Fn3-90), Gly27849Val (Fn3-90), Pro31732Leu 
(Fn3-119) and Arg31847Pro (Fn3-120) were introduced into 
the wild type vectors by point mutagenesis.
For expression in mammalian cells, DNA encoding two 
titin regions spanning Ig-125, Fn3-47—Fn3-49, Ig-126 
(Ig-125-126) and Ig-141, Fn3-90, Fn3-91, Ig-142 (Ig-141-
142) were amplified from a human skeletal-muscle cDNA 
library and inserted into a pCMV-GFPC2 vector. The Val-
22232Glu (Fn3-49) and Gly27849Val (Fn3-90) variants 
were introduced by point mutagenesis.
Protein expression and purification
pET6His vectors encoding 6-histidine-tagged titin WT and 
variant domains were transformed into E. coli strains (DE3)-
BL21 (Agilent) RIPL or K12 Shuffle (NEB, Ig-87 only) and 
cultured in Luria Bertani or Terrific Broth media at 18 °C 
overnight following induction of protein expression by addi-
tion of isopropyl-b-D-thiogalactopyranoside to 0.5 mM at an 
absorbance at 600 nm of 0.4–0.8.
For Western blot solubility analysis in bacteria, ~ 1 mL 
cell pellet was resuspended in BugBuster (Merck) sup-
plemented with DNase I and  cOmplete® protease inhibi-
tor (Sigma). Following incubation at room temperature for 
30 min, the soluble and insoluble fraction were separated by 
centrifugation at 18,000 g at 4 °C for 30 min. In HEK293, 
cells were washed in PBS, lysed in Tris-buffered saline with 
0.4% NP-40, 2 mM DTT and the soluble and insoluble frac-
tions were separated as above. Samples corresponding to 
the total and soluble fractions were mixed with SDS-PAGE 
sample buffer.
For biophysical analysis, 1 L cell pellets were re-sus-
pended in lysis buffer supplemented with protease inhibitors, 
incubated with lysozyme and sonicated on ice. Following 
incubation with DNase I, the soluble and insoluble fractions 
were separated by centrifugation at 17,000 g for 40 min at 
4 °C. Proteins expressed in the soluble fraction were purified 
by nickel affinity chromatography followed by size exclusion 
chromatography. Proteins expressed in the insoluble fraction 
were solubilised in 8 M urea and purified by nickel affin-
ity chromatography under denaturing conditions. Attempts 
were made to refold the domains by step-wise dialysis into 
lower concentrations of urea, followed by size exclusion 
chromatography.
Western blotting
Total and soluble protein fractions from expression tests 
were separated by SDS-PAGE on a 4–20% precast gel 
(BioRad) and low-density agarose-assisted polyacrylamide 
gels were used for running patient tissue samples, with 
both then transferred to nitrocellulose. Expressed protein 
was detected by incubation with anti-HIS (Novagen 70796, 
1:1000 dilution) or anti-GFP (Roche 11814460001, 1:1000) 
primary antibody followed by HRP-tagged anti-mouse sec-
ondary antibody (DAKO P0260, 1:1000). Endogenous titin 
in patient samples was detected by incubation with anti-
titin antibodies T12 [13], A170, M2, M8-M9 and Mis6 
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(generated for this work, Dundee Cell Products, UK) fol-
lowed by incubation with secondary antibody as above. HRP 
activity was measured on a BioRad imager following incu-
bation with chemiluminescent substrate (GE Healthcare).
Differential scanning fluorimetry
The melting temperature  (Tm) was obtained for selected titin 
domains according to the protocol outlined in Niesen et al. 
[39]. 20 µM protein was mixed with 20 X SYPRO Orange 
(ThermoFisher), dispensed in a BioRad qPCR plate, and 
heated from 25–95 °C at a rate of 1 °C/min in a MX3005p 
qPCR machine (Agilent). Fluorescent emission at 610 nm 
following excitation at 492 nm was measured, with the 
resulting curve defined in Excel, and the  Tm calculated in 
GraphPad (Prism).
Circular dichroism spectroscopy
The UV and CD spectra of selected titin domains at 40 µM 
were acquired on an Applied Photophysics Chirascan Plus 
spectrometer at a path length of 0.5 mm (190–260 nm) or 
10 mm (240–400 nm). For thermal denaturation experi-
ments, from 20 °C, samples were cooled to 6 °C, heated to 
94 °C at a rate of 1 °C/min with a 2 °C step size and then 
cooled back down to 6 °C.
Nuclear magnetic resonance
1D 1H spectra of selected titin domains at 100–200 µM were 
acquired at 500 and 700 MHz on Bruker Avance spectrom-
eters equipped with cryoprobes at 298 K. Water suppression 
was achieved by Watergate in combination with excitation 
sculpting [25]. A total of 8192 points were recorded for each 
FID with a spectral width of 16 ppm. Prior to Fourier trans-
formation of the FIDs exponential line broadening with a 
line width of 8 Hz was used. Spectra were processed using 
Topspin 3.2 (Bruker).
Mammalian cell transfection, fixation 
and immunostaining
NRCs were prepared according to [31], and C2C12 and 
HEK293 cells were prepared following standard proto-
cols. NRCs, C2C12 and HEK293 cells were transfected 
using Escort III (Sigma), Lipofectamine 3000 (Invitrogen) 
and Escort IV (Sigma), respectively, according to manu-
facturer’s instructions. Following incubation at 37 °C, 5% 
 CO2 for 24–48 h for NRCs and HEK293 cells and up to 
14 days for C2C12 myoblasts to allow differentiation into 
myotubes, cells were prepared according to [12]. Cells 
were stained with primary antibodies against myosin heavy 
chain (clone A4.1025) [9], obscurin domain O59 [61], titin 
Z1Z2 [15], p62/SQSTM1 (Abcam, ab41116161) and ubiq-
uitin (Merck, FK2, 04–263) followed by Cy3 or Cy5-conju-
gated goat anti-rabbit or anti-mouse IgG (H + L) secondary 
antibodies (Jackson ImmunoResearch ML 115–165-146, 
115–175-146, 111–175-144 and BioRad STAR36D549GA) 
and imaged on an LSM510 (Zeiss) or SP5 (Leica) confo-
cal microscope. Antibodies were diluted 1:100 prior to 
incubation.
Quantification of sarcomeric GFP‑titin localisation
Line scans of 5–6 sarcomeres in an NRC were averaged to a 
single sarcomere using the anti-obscurin signal to measure 
sarcomere length, and the Z-disk/I-band region was defined 
as the region below the midway positions between the peak 
of the anti-myosin signal in the A-band and the trough of 
that signal at the Z-disk. The GFP-titin fragment localisation 
in the I-band/Z-disk region was quantified as a percentage 
of total GFP signal in 4–5 different cells per titin fragment.
Statistics
The statistical significance for differences of CADD Phred 
scores between the variants in the study, ClinVar and 
GnomAD cohorts was calculated using the Kruskal–Wal-
lis test, and the differences between WT and variant titin 
fragment Z-disk localisation in NRCs and their solubility 
when expressed in HEK293 cells was calculated using the 
student’s t test.
Study approval
All individuals were enrolled under appropriate procedures 
and in accordance with ethical guidelines at their local 
institutions, with written informed consent obtained from 
all subjects or their legal guardians for genetic studies. The 
study was conducted in accordance with approvals by the 
National Research Ethics Service (NRES) London- West 
London & GTAC (Reference: 06/Q0406/33), the research 
ethics committee of Great Ormond Street Hospital (Refer-
ence: 00/5802), and Guy’s & St Thomas NHS Foundation 
Trust (Reference: RJ110/N231).
Results
Patient demographics and family histories
Thirty patients from 23 families were included in the study, 
19 of them male and 11 female. Twenty-seven patients were 
still alive and 3 had died, at 10 weeks, 3 months and 54 years 
of age, respectively. Age at last follow-up (or death) ranged 
from 10 to 71 years (median 19 years). In 14 patients there 
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was a family history of neuromuscular disorders, and in 11 
patients there was a family history of cardiac disease in a 
first degree relative, comprising both confirmed cardiomy-
opathies and/or sudden unexplained deaths of presumably 
cardiac causes. No parent had a skeletal myopathy (Table 1, 
Supplementary Table 2).
Clinical features
The key clinical features are summarized in Table 1 and 
illustrated in Fig. 1. Presentation was most commonly in 
the neonatal period (n = 11) or antenatally (n = 7), and less 
frequently later in infancy (n = 7) or early childhood (n = 5). 
The most common presentation was hypotonia (n = 16) and/
or weakness (n = 14), often pronounced axially, with asso-
ciated feeding difficulties (n = 14) frequently necessitating 
nasogastric tube feeding (n = 6). In two cases, respiratory 
impairment was severe enough to necessitate intubation and 
ventilation in the neonatal period. Eight patients had marked 
dysmorphic features, in the context of congenital cardiac 
abnormalities, prompting an initial suspicion of Noonan’s 
syndrome in 2 cases.
Early motor development was delayed in 22 patients. 
Twenty-three patients achieved and maintained the abil-
ity to walk independently for variable distances, except 
one patient who lost independent ambulation at the age of 
14 years. Fifteen patients were at least intermittent wheel-
chair users. Twenty-one patients showed an overall stable 
course, whereas progression was rapid in 7, two of whom 
died within the first year of life from cardiorespiratory 
causes (no further data available n = 2). Patient 19 died aged 
54 years, also due to cardiorespiratory causes.
On examination, weakness was typically pronounced 
axially and proximally. Six patients had additional distal 
Fig. 1  Typical features in TTN-related myopathies. This 38-year-old 
patient presented with hypotonia and ventricular non-compaction 
from birth. Subsequently, his motor development was delayed. His 
stature was short, he had a myopathic face with pronounced pto-
sis (a), multiple contractures prominently involving the elbows and 
shoulders (b, c), and spinal rigidity (d). He developed a dilated car-
diomyopathy from his teens. The most prominent feature on muscle 
biopsy are numerous centralized nuclei (e) leading to an initial diag-
nosis of CNM, but there were additional cores (f, g) and few nema-
line rods (h) on EM. Scale bars 40 µm (e, f), 2 µm (g) and 1 µm (h). 
Lower extremity muscle MRI from another patient showing promi-
nent hamstring involvement in the thigh (i). Scale bar 5 cm, L indi-
cates left side
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involvement, involving ankle dorsiflexion and the tibialis 
anterior. Most patients had generalized muscle wasting, but 
hypertrophy of the calves was found as a rare feature in one 
family. With few exceptions (n = 2), muscle involvement 
was symmetrical. Patient 15 described distinct episodes of 
periodic weakness usually occurring after illness or extreme 
exercise. Combined with the presence of dysmorphic fea-
tures and a cardiomyopathy, this lead to an initial considera-
tion of a diagnosis of Andersen-Tawil Syndrome; screening 
for common periodic paralysis-associated genes was nega-
tive. Myopathic facial involvement was variable. Ptosis was 
present in 5 patients (no data n = 5) but extraocular muscle 
involvement was universally absent. Scoliosis (n = 22) with 
or without spinal rigidity (n = 13) was very common and in 2 
cases already present early in life. Seven patients underwent 
spinal fusion but others could be managed conservatively. 
Contractures were a very prominent feature (n = 17) and in 
7 cases already present at birth. Joint involvement ranged 
from isolated tendon Achilles tightness to an “Emery-
Dreifuss-like” picture, to extensive arthrogryposis affecting 
most joints and representing a major cause of disability in 
individual cases. In contrast, many patients had additional 
or isolated joint hyperlaxity (n = 12), often affecting the 
shoulders, hands, fingers and knees, the latter associated 
with recurrent patella subluxations in some individuals. 
Bone fractures (n = 9) after often relatively minor trauma 
were also prominent, and in one case already present in the 
neonatal period.
Cardiac involvement was present in 14 patients, com-
prising congenital cardiac defects (n = 4) including atrial 
septal defects (ASD), ventricular septal defects (VSD) and 
left-ventricular non-compaction, or a combination of the 
above, and/or a (dilated) cardiomyopathy (n = 13), and/or 
the presence of arrhythmias (n = 10), either in the context 
of an already existing cardiomyopathy or preceding the lat-
ter. Twenty-six patients had evidence of respiratory involve-
ment indicated by either frequent respiratory infections or 
overt respiratory impairment, with 14 requiring some kind 
of ventilatory support, ranging from (mainly nocturnal) non-
invasive ventilation (n = 12) to almost permanent ventilation 
through a tracheostomy (n = 2). Eleven patients had persis-
tent bulbar involvement with chewing and swallowing dif-
ficulties, requiring gastrostomy insertion in more than half 
(n = 6) (Table 1, Supplementary Table 2).
Fig. 2  Localisation and type of variants along Titin in our  patient 
cohort. N2A, N2B and IC transcripts detailed, with exons absent in 
N2B highlighted on plot in light grey and exons absent in both N2A 
and N2B in dark grey. Positioning of antibodies used in immunofluo-
rescence studies also indicated (green diamonds). DNA and protein 
numbered according to the IC transcript NM_001267550
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Investigations
Creatine kinase levels were normal in 19 patients and mildly 
elevated (up to 500 IU/l) in 3 (no data n = 8). Electromyogra-
phy/nerve conduction studies performed in 14 patients were 
either normal (n = 4) or showed mild myopathic abnormali-
ties (n = 10) but never neurogenic changes. Thirteen patients 
underwent muscle imaging, including muscle ultrasound 
(n = 2), muscle CT (n = 2) and muscle MRI (n = 9). Muscle 
imaging showed a variable pattern with some consistencies, 
notably concerning prominent involvement of the paraver-
tebral muscles, the proximal lower limbs, in particular the 
hamstring muscles, and the tibialis anterior in the lower leg.
Histopathological features
The principal histopathological diagnoses are listed in 
Table 1 and Supplementary Table 2, and illustrated in Fig. 1. 
Based on the most prominent feature on muscle biopsy, the 
most common histopathological diagnoses in our cohort 
were, with descending frequency, Multi-minicore Disease 
(MmD) (n = 10), CNM (n = 9), Congenital Fibre Type Dis-
proportion (CFTD) (n = 5), CM with non-specific or unusual 
features (n = 3) and Type 1 predominance/uniformity (n = 1). 
Two patients did not undergo a muscle biopsy because the 
histopathological diagnosis had already been established in 
a sibling with similar clinical features.
The typical histopathological presentation was with a 
combination of abnormalities rather than a “pure” histo-
pathological picture; these abnormalities included, with 
descending frequency, (1) core-like structures (n = 21) rang-
ing from unevenness of oxidative stains to minicores and, 
less frequently, central cores (confirmed on electron micro-
graphs where performed); (2) internalized nuclei, often cen-
tral (n = 18); (3) and increased fibre size variability (n = 13), 
often but not always fulfilling the formal criteria for CFTD.
Of note, despite the multitude of other structural abnor-
malities, nemaline rods were a very rare feature only seen 
in one patient. Increases in connective tissue and, less fre-
quently, fat were occasionally observed (n = 8). Rare ultras-
tructural findings not previously associated with TTN-related 
myopathies included (“Mallory-like”) cytoplasmic inclusion 
bodies (n = 2) and fingerprint bodies (n = 1).
Genetics
TTN variants identified in our patients are summarized in 
Table 2, Supplementary Table 3 and Fig. 2. In 18 patients, 
compound heterozygosity in trans or homozygosity for 
TTN variants was confirmed; in 3 patients, one TTN vari-
ant and absence of the second variant was confirmed in 
one parent; due to lack of any parental DNA, the inherit-
ance pattern of TTN variants could not be confirmed in 
9 patients. Thirteen of the TTN variants identified were 
missense and 33 variants were expected to be truncating. 
Three groups of variants were observed: (1) two truncating 
variants (patients 2, 3, 5–14, 28 and 29), (2) one truncating 
variant and one missense variant (patients 1, 4, 15–24, 27 
and 30) and (3) a homozygous missense variant (patients 
25 and 26).
Truncating variants were either stop-gained, insertion/
deletion with frameshift or splice donor site variants. Two 
patients had the same genotype of one truncating variant 
and two duplications, which were presumed to result in a 
truncated transcript. For patients with at least one of their 
two truncating variants occurring in exons whose expres-
sion is restricted to skeletal muscle (skeletal tandem-
immunoglobulin and PEVK regions), cardiac symptoms 
were not present at the time of last follow-up.
Eight patients had additional variants in the TTN gene: 
patients 6 and 7 had the second duplication mentioned 
above. Patient 24 had an additional missense variant in 
the unfolded PEVK region and patient 27 had one residue 
deleted in the linker between two immunoglobulin (Ig) 
domains; both variants are beyond the scope of this study. 
In addition, patient 24 had a missense variant C-terminal 
and in cis of a constitutively expressed truncating vari-
ant. Patient 29 had a missense variant (Leu18237Pro) in 
Fn3-20, which is included in this study, in addition to two 
truncating variants. Finally, patients 9 and 10 had a Leu-
to-Val variant in Fn3-27 and patient 11 had an Ala-to-Val 
variant in Ig-114, respectively. These two variants are cur-
rently under investigation, although the conserved nature 
of the mutations suggests they are non-disrupting and the 
patient phenotypes can be explained by their two other 
variants. In 5 patients additional variants were identified 
in other genes through next generation sequencing, includ-
ing a potentially pathogenic variant in MYBPC3 in patient 
29 [36] and a variant in RYR1 previously associated with 
the malignant hyperthermia (MH) susceptibility trait in 
patient 1.
Both missense and truncating variants were spread 
across the entire length of titin and occurred both in dif-
ferentially spliced regions, notably the I-band region, and 
constitutively expressed regions, e.g. the Z-disk, A-band 
and M-band regions (Fig. 2). Except for three TTN muta-
tions (Val22232Glu, Pro31732Leu and Trp34072Arg), 
the missense variants included in the study had not been 
previously associated with early-onset titinopathies and 8 
out of 12 were unique, i.e. not present in gnomAD. The 
Fn3-119 Pro31732Leu variant (homozygous in patients 25 
and 26) has been previously reported as a mutation linked 
to HMERF, albeit with variable penetrance and considered 
dominant, recessive, or neutral [32, 41, 46, 47]. The rare 
TTN variant Trp34072Arg (minor allele frequency, MAF 
8.21E-06 in gnomAD) in TK (patient 30) has previously 
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Fig. 3  Immunofluorescence 
analysis demonstrates the 
sarcomeric integration of 
truncating and missense titin 
variants in patients 22, 24 and 
29. Cryosections of heart tissue 
(patients 22 and 24) and skeletal 
muscle (patient 29) were stained 
for N-terminal Z-disk titin (red; 
Z1Z2 antibody) and C-terminal 
M-band titin (green; M2, Mis6 
and M8-M9 antibodies). Note 
that only the C-terminal epitope 
Mis6 is absent for patient 29, 
carrying two truncating muta-
tions before the Mis6 epitope. 
Scale bar: 10 µm
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been associated with congenital hereditary myopathy 
(patient 5 in [7]).
Genotype–phenotype correlations
Several individuals with compound-heterozygous trun-
cating variants were identified with strongly overlapping 
phenotypes. Compound heterozygous truncating variants 
were identified predominantly in the I-band and A-band; 
their pathogenic role in congenital myopathies is increas-
ingly documented [6]. Phenotypic penetrance of truncating 
variants seems to be entirely driven by exon usage: skel-
etal muscle-only penetrance is observed when one or both 
truncating variants reside in an exon not expressed in the 
cardiac-specific N2B transcript. Cardiomyopathy is not a 
regular clinical feature in these patients and does not seem 
prevalent in the parental carriers (Table 2).
Phenotypic penetrance of patients with one truncating 
and one missense variant is less clear. Whilst four patients 
with both variants expressed in the predominant skeletal 
(N2A) and cardiac isoforms (N2B) have been diagnosed 
with a cardiomyopathy (patients 18, 19, 20 and 24 with an 
age range of 32–71 years), patient 1 (37-years-old) has not. 
Additionally, the patients homozygous for the HMERF-
linked Pro31732Leu variant in Fn3-119 (patients 25 and 26, 
31 and 25-years-old respectively) have not been diagnosed 
with a cardiomyopathy but show myopathic symptoms only. 
It should be noted, however, that cardiomyopathy is not a 
consistent feature for dominantly-inherited HMERF muta-
tions in the Fn3-119 domain, which is expressed in all titin 
transcripts [55]. The parental carriers and two heterozygous 
siblings of patients 25 & 26 are unaffected and there is no 
family history of myopathy or early respiratory failure. Two 
patients (15 and 16) with the missense variant but not the 
truncating variant expressed in the N2B isoform of titin have 
been diagnosed with a cardiomyopathy (Table 2).
Tissue staining of patients 22, 24 and 29
Heart tissue from patients 22 (truncating variant in the 
kinase domain and Val22232Glu in Fn3-49), and 24 
(p.Gly27849Val in Fn3-90 and p.Arg21201* in Ig-123), 
Fig. 4  Crystal structures or homology models highlighting atomic 
environment of residue mutated in patient missense variants. The 
side-chains of residues (and main chain for Fn3-90) mutated in 
patients are represented as labelled green sticks, with surround-
ing side-chains of interest also represented as sticks. Polar contacts 
are shown via yellow dashed lines. Ig-1 structure is from the crystal 
structure of first two titin domains, PDB code 2a38. All other models 
were generated from TitinDB. Images generated using PyMol 2.1.1
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and skeletal muscle from patient 29 (truncating variants 
in Fn3-123 and Ig-166, with an additional Leu18237Pro 
missense variant in Fn3-20) was available for analysis. 
All studied truncations are C-terminal to Z-disk titin, 
which was therefore used as a positional marker for sar-
comere integrity (antibodies T12 and Z1Z2) [13, 15] 
and counter-stained with antibodies against M-band Ig-
domains 161 (M2), 167–168 (M8-9) and the inter-domain 
insertion between Ig-166 and Ig-167 (Mis6 [16]) (Fig. 3). 
For patients 22 and 24, staining of M-band titin showed 
that at least one allele was fully translated and integrated 
into the sarcomere, with no evidence of the missense 
variant on the non-truncated allele preventing this. For 
patient 29, staining revealed that titin was integrated into 
the sarcomere with the Mis6 insertion just N-terminal to 
the truncation in Ig-166 present, but the most C-terminal 
staining by an antibody against Ig-167 (M8-9) absent, 
as predicted by the patient genotype. There was no evi-
dence of exon skipping enabling detectable translation of 
C-terminal titin (Fig. 3).
Western blotting of tissue from patients 22, 24 
and 29
Western blots of low-density agarose-assisted polyacryla-
mide gels were run using the muscle tissue described above. 
Probing the blots with antibodies against epitopes near the 
N- and C-termini of titin confirmed that the full-length 
protein was detectable in tissue from patients 22 and 24, 
but absent in patient 29 (Supplementary Fig. 1), in which 
the C-terminal epitope Mis6 was not detectable, in excel-
lent agreement with the genotype. A band detected only by 
antibody T12 was present in patient 24 tissue, as would be 
predicted for an N-terminal titin fragment of ~ 1.2 MDa, 
providing evidence of expression of the truncated allele in 
patient 24.
Characterisation of missense variants (i–iii)
(i) Structural and bioinformatics analyses
Compared to truncating variants, the missense variants pose 
a significant diagnostic challenge. The 13 missense variants 
in our cohort that are not predicted to alter splice sites are 
found in the Ig, Fn3 or kinase domains of titin. The 12 mis-
sense variants in the Ig and Fn3 domains were modelled to 
assess their impact using either crystallographic structures 
or homology-based structural models generated by TITINdb 
[29] (Fig. 4). All mutated residues excluding Leu18237 in 
Fn3-20 are predicted to be in the core of their domain with 
quotient solvent accessible surface areas, Q(SASA), below 
0.15 (residues with Q(SASA) > 0.3 are defined as being sol-
vent accessible) [5] (Supplementary Table 4).
The crystal structure of Ig-1, which harbours the 
Ala82Asp variant, shows the Ala82 sidechain facing towards 
the core of the domain, mediating hydrophobic contacts with 
a neighbouring isoleucine. Mutation to aspartic acid would 
introduce a charged residue into the core of the domain as 
well as result in steric clashes with neighbouring residues.
Cys5054 in domain Ig-33 has been implicated in intra-
molecular disulfide bond formation [37], which have been 
shown to stabilise immunoglobulin domains [19, 37]. Muta-
tion to arginine would disrupt this disulfide bond formation, 
with the bulky, charged variant residue likely to further dis-
rupt domain folding. A cysteine-to-arginine variant is also 
found in Fn3-12 (Cys17051Arg), with this cysteine found at 
the position typically occupied by the second proline in the 
PXXP motif at the N-terminal of fibronectin domains. The 
introduction of a bulky, charged arginine facing towards the 
core of the domain is likely to disrupt its folding.
Two variants are predicted to mutate residues contributing 
to the hydrophobic domain core: Trp16471Cys exchanges a 
canonical tryptophan in Fn3-7 for the small cysteine and 
Val22232Glu introduces a charged glutamic acid into the 
core of Fn3-49.
Three variants introduce a bulky sidechain into a loop 
connecting beta strands, facing inwards towards the domain 
core: Ala13715Glu in Ig-87, Gly27849Val in Fn3-90 and 
the HMERF-linked Pro31732Leu in Fn3-119. Asn16133 is 
similarly positioned in Fn3-4, but the mutation to lysine is 
predicted to disrupt hydrogen bonding to three neighbour-
ing residues.
Two variants identified mutate an outward-facing beta-
sandwich arginine to a proline: Arg25480Pro in Fn3-73 is 
predicted to abolish a salt bridge with a neighbouring glu-
tamic acid, while Arg31847Pro in Fn3-120 would disrupt 
hydrogen bonds to two neighbouring residues. In both cases, 
the main-chain hydrogen bond stabilising the beta sheet con-
tributed by the lysine amide group would be lost.
The missense variant in Fn3-20 found in addition to 
the two truncating variants in patient 29 is predicted to 
abolish the main-chain hydrogen bond of Leu18237 to a 
neighbouring tyrosine side-chain upon mutation to proline. 
The Trp34072Arg mutation in the kinase domain has been 
described previously [7].
Strikingly, five of the missense variants mirror muta-
tions in other titin domains linked to disease; that is, the 
variants structurally align with disease-causing mutations 
in homology models or crystal structures of other titin 
domains. Ala82Asp in Ig-1 is the exact structural image of 
a recently reported Ala178Asp mutation in Ig-2, which was 
implicated in causing an autosomal dominant cardiomyo-
pathy with features of left-ventricular non-compaction [22]. 
Four other variants mirror mutations in Fn3-119 linked to 
HMERF: the Cys17051Arg variant in Fn3-12 mirrors the 
most frequent HMERF mutation (Cys31712Arg), while 
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Fn3-7 Trp16471Cys, Fn3-4 Asn16133Lys and Fn3-90 Gly-
27849Val mirror the recently identified HMERF-linked 
mutations Trp31729Cys, Asn31786Lys and Gly31791Val 
in Fn3-119, respectively [42]. Additionally, three of these 
positions in Fn3-119 were also mutated to other residues 
in the HMERF cohort: Cys31712Tyr, Trp31729Leu, 
Trp31729Arg, Gly31791Arg and Gly31791Asp.
The missense variants were also assessed using TITINdb 
for their occurrence in reference SNP databases (gnomAD) 
and by sequence (Condel) and structure-based (mCSM) 
modelling of mutational impact (Supplementary Table 4). 
Condel integrates the output of several sequence-based 
predictors of mutational impact to provide a “deleterious-
ness score” between 0 and 1, with variants scoring above 
0.5 considered deleterious [20]. The impact of a variant can 
also be correlated with the changes in the atomic distances 
surrounding the mutant residue, provided that reliable struc-
tural information is available, using the “mutation Cutoff 
Scanning Matrix” (mCSM) algorithm that predicts changes 
of free energy (in kcal/mol; [49]). We observed that all mis-
sense mutations in the study show negative mCSM values, 
from − 0.15 to − 2.82 kcal/mol, indicative of a destabilising 
effect. However, negative mCSM values are also observed 
for some missense variants in gnomAD with MAF well over 
Fig. 5  Western blot assessing 
soluble expression of WT and 
missense variant-containing 
titin domains. Bacterial cultures 
expressing His-tagged titin 
domains were lysed, separated 
into total and soluble fractions, 
run on Western blot and probed 
with anti-His tag antibody
Table 3  Summary of effects of patient cohort and common missense variants on soluble domain expression in E. coli and their thermal stability 
following purification
Melting temperatures measured using differential scanning fluorimetry (no superscript) or circular  dichroism(a, b). Measurements labelled (b) from 
(7)
Patient Missense variant Domain Variant 
soluble?
WT Tm (°C) Variant Tm (°C) Δ domain stability (°C)
1 p.Ala82Asp Ig-1 No 71.2 ± 0.1 (n = 4) 34.0 ± 0.8 (n = 4) − 37.1
8 p.Cys5054Arg Ig-33 No – – N/A
15 and 16 p.Ala13715Glu Ig-87 No – – N/A
17 p.Asn16133Lys Fn3-4 No – – N/A
18 and 19 p.Trp16471Cys Fn3-7 Yes 75.2 ± 0.6 (n = 4) 43.4 ± 0.7 (n = 4) − 31.8
20 and 21 p.Cys17051Arg Fn3-12 No – – N/A
22 p.Val22232Glu Fn3-49 No 59.2 ± 0.1 (n = 5) – Unfolded
23 p.Arg25480Pro Fn3-73 No – – N/A
24 p.Gly27849Val Fn3-90 No 61.5 ± 0.2 (n = 3) – Unfolded
25 and 26 p.Pro31732Leu Fn3-119 No 49.2 ± 0.1 (n = 3) 31.8 ± 0.1 (n = 3) − 17.5
27 p.Arg31847Pro Fn3-120 No 51.7 ± 0.7 (n = 4)/49.7a (n = 1) – Unfolded
29 p.Leu18237Pro Fn3-20 Yes 80.4a (n = 1) 63.5&78.0a (n = 1) − 16.9/− 2.4
30 p.Trp34072Arg Kinase Yes 59b (n = 1) 42&57b (n = 1) − 17/− 2
Common 
variant
p.Arg24947Cys Fn3-69 Yes 62.6 ± 0.1 (n = 3) 62.1 ± 0.2 (n = 3) − 0.5
Common 
variant
p.Ile27775Val Fn3-90 Yes 61.5 ± 0.2 (n = 3) 63.5 ± 0.1 (n = 3)  + 2.0
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1%. Condel scores all missense variants bar Cys17051Arg 
and Leu18237Pro as deleterious, but also scores some com-
mon missense variants likewise (Supplementary Table 4). 
This highlights the inadequacy of most commonly used pre-
diction algorithms to reliably assess TTN missense variants.
Further bioinformatic analysis was undertaken by com-
paring the CADD phred scores for the study cohort to scores 
for all Titin missense variants in the gnomAD and ClinVar 
cohorts. CADD values are derived from multiple annota-
tions and contrasts simulated variants with those that have 
survived natural selection, with a higher score for more "del-
eterious" variants. Thirteen out of the 14 missense variants 
in the cohort were calculated to be in the top 1% of delete-
rious missense variants across the genome, but there was 
no significant difference between the cohort and the Titin 
gnomAD missense variants (P = 0.7). There was a signifi-
cant difference when comparing the gnomAD and ClinVar 
cohorts (P = 0.04) (Supplementary Fig. 2).
Adding to the ambiguity, the mCSM, Condel and CADD 
values for each missense variant in the cohort do not corre-
late (Supplementary Fig. 2). We therefore decided to experi-
mentally validate the stability of wild type and mutant titin 
domains to ascertain their destabilising effects. Addition-
ally, localisation studies of two missense variants with both 
cardiac and skeletal phenotypes were performed in cardio-
myocytes, skeletal myocytes and a non-muscle model cell 
line, HEK293 cells.
(ii) Expression of wild type and variant domains in bacteria
All titin fibronectin and immunoglobulin domains contain-
ing a missense variant in the study cohort were expressed 
in bacteria, and the expression of wild type and variant 
recombinant protein was assessed by separating the total 
and soluble fractions of the cells and assaying via western 
blot (Fig. 5, Supplementary Figs. 3 and 4). For comparison, 
we also expressed and assayed two domains with common 
missense variants (MAF over 0.1) with conflicting classi-
fication of pathogenicity: Arg24947Cys in Fn3-69 (classi-
fied as deleterious by Condel) and Ile27775Val in Fn3-90 
(classified as neutral); their high frequency in the general 
population rules out a major disease-association. Of the 11 
Ig and Fn3 domains tested, only 2 disease cohort variants 
were solubly expressed (Fn3-7 Trp16471Cys, and Fn3-20 
Fig. 6  Biophysical characterisation of WT and missense variant-
containing titin domains. a 1D NMR of Fn3-49 WT (black) and Val-
22232Glu (lilac). b Differential scanning fluorimetry of Fn3-119 WT 
(black) and Pro31732Leu (lilac). c thermal denaturation measured by 
circular dichroism of Fn3-120 WT (left) and Arg31847Pro (right)
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Leu18237Pro), compared to all wild type domains and the 
common missense variants (Fig. 5; Table 3). This strongly 
suggested an inability of the bacterial translation machin-
ery to correctly fold the majority of disease-linked missense 
variant domains.
(iii) Biophysical characterisation
Five predicted pathogenic domains expressed in the insolu-
ble fraction were purified under denaturing conditions, 
and attempts were made to refold the protein. Three vari-
ants—Val22232Glu (Fn3-49), Gly27849Val (Fn3-90) and 
Arg31847Pro (Fn3-120)—could not be refolded under any 
tested condition, as measured by either 1D NMR or circular 
dichroism (CD).
The 1D NMR spectra of Fn3-49 and Fn3-90 WT were 
typical of a folded protein, with dispersed peaks in the − 1 to 
0.5 ppm region corresponding to methyl hydrogens of side-
chains in a buried, hydrophobic core and clear dispersion 
of amide shifts between 6–9 ppm. Conversely, the spectra 
of Fn3-49 Val22232Glu and Fn3-90 Gly27849Val lacked 
peaks upfield of 0.5 ppm and presented broader line widths, 
both indicative of an unfolded protein (Fig. 6, Supplemen-
tary Fig. 5).
The conformation and thermal stability of Fn3-20 and 
Fn3-120 WT and missense domains were assessed by 
Fig. 7  Confocal immunofluorescence microscopy of neonatal rat 
cardiomyocytes expressing GFP-tagged titin Ig-125-126 WT and 
Val22232Glu, and Ig-141-142 WT and Gly27849Val. Cells were 
counterstained with antibodies against myosin heavy chain (red) and 
Obscurin O59 (blue, marking the M-band); GFP-titin in green. Small 
arrows mark the A-band doublets labelled by the A4.1025 mono-
clonal antibody against myosin heads [9] and large arrows mark the 
intercalated disk. Scale bar: 10 µm
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thermal denaturation CD. At 20 °C, the WT domains and 
Fn3-20 Leu18237Pro had a spectrum typical of a beta sheet-
containing protein, with a positive circular dichroism signal 
around 225 nm, with this signal being lost during heating to 
95 °C, due to unfolding of the protein (Fig. 6, Supplemen-
tary Fig. 6). Fn3-20 Leu18237Pro showed a two-step unfold-
ing curve, with the first Tm 16.9 °C lower than that the sin-
gle Tm of the WT domain (Supplementary Fig. 6; Table 3). 
In contrast to Fn3-120 WT, at 20 °C Fn3-120 Arg31847Pro 
had no positive CD signal, indicative of an unfolded protein, 
a state further confirmed by the lack of change in spectra 
upon heating (Fig. 6). The missense variant Trp34072Arg 
has previously been shown by this technique to destabilise 
titin’s kinase domain by 17 °C [7] (Table 3).
The thermal stability of seven domains and their mis-
sense variants was also measured using differential scan-
ning fluorimetry (Fig. 6, Supplementary Fig. 7, Table 3). 
The only disease-linked variant to be solubly expressed, 
Fn3-7 Trp16471Cys, caused a reduction of the domain’s 
thermal stability of 31.8 °C. Two variants could be refolded 
following purification under denaturing conditions: Ig-1 
Ala82Asp and Fn3-119 Pro31732Leu. Ala82Asp reduced 
Ig-1′s thermal stability by 37.1 °C (Supplementary Fig. 7), 
and Pro31732Leu destabilised Fn3-119 by 17.5 °C (Fig. 6). 
Fig. 8  Confocal microscopic images showing expression of titin frag-
ments in C2C12 myocytes. GFP-tagged titin fragments Ig-125-126 
WT and Val22232Glu, and Ig-141-142 WT and Gly27849Val, were 
transfected into C2C12 myoblasts and seven days post-transfection 
were fixed and stained with antibodies against p62/SQSTM1 and con-
jugated ubiquitin (c-Ub). 4–8 transfected cells per titin fragment were 
imaged, with representative cells shown here. Only the GFP and p62/
SQSTM1 channels were used for the merged image. Arrows indicate 
examples of colocalisation of mutant titin, p62/SQSTM1 and conju-
gated ubiquitin
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To benchmark these observations, we assessed the thermal 
stability of the two common missense variants described ear-
lier. Both variants showed no impact on domain stability in 
our experimental approach, with Ile27775Val even showing 
a modest increase in thermal stability (Table 3). As expected 
for domains that could not be refolded, the variant domains 
of Fn3-49, Fn3-90 and Fn3-120 did not produce an unfold-
ing curve, in contrast to their corresponding WT domains 
(Supplementary Fig. 7).
Localisation of titin fragments in cardiomyocytes
To assess the expression and localisation in a more native 
environment, WT and variant titin fragments spanning 
domains Ig-125-126 and Ig141-142, encompassing the Fn3-
49 Val22232Glu and Fn3-90 Gly27849Val variants, respec-
tively, were transfected into neonatal rat cardiomyocytes 
(NRCs). Immunofluorescence confocal microscopy showed 
a clear difference in the subcellular targeting of the WT and 
variant constructs (Fig. 7, Supplementary Fig.8). Whilst the 
expressed WT fragments were diffuse with some localising 
in doublets with myosin heavy chain (where A-band titin 
is natively found) the variant fragments showed a signifi-
cant increase in localisation to the Z-disk (Supplementary 
Fig. 9). There was also evidence of aggregation, particularly 
at the intercalated disc, suggesting a failure of the mam-
malian muscle translation system to correctly fold the vari-
ant protein. The functional impact of the misfolded protein 
therefore appears to extend over several domains, as shown 
by the mis-localisation of the variant fragments.
Expression of titin fragments in C2C12 myoblasts
Ig-125-126 WT and Val22232Glu, and Ig141-142 WT 
and Gly27849Val were also transfected into C2C12 myo-
blasts. The WT fragments showed diffuse staining but 
both missense variants largely formed speckles, frequently 
colocalising with both p62/SQSTM1, an autophagosome 
marker, and conjugated ubiquitin, which labels misfolded 
proteins targeted for degradation (Fig. 8). Only C2C12 
myoblasts transfected with WT titin fragments could be 
cultured for long enough to differentiate into myotubes; 
no C2C12 myoblasts transfected with variant fragments 
were observed to differentiate into myotubes (data not 
shown).
Expression of titin fragments in HEK293 cells
The four titin fragments described above were transfected 
into HEK293 cells and their expression was assessed. The 
WT fragments largely showed a diffuse cytosolic locali-
sation, with infrequent observations of the fragments co-
localising with p62/SQSTM1 (Supplementary Fig.  10, 
Supplementary Fig. 11). In contrast, the variant fragments 
consistently appeared aggregated, with many examples of 
colocalisation with p62/SQSTM1. To assess the solubility 
of the expressed fragments, transfected cells were harvested, 
lysed and the total and soluble fractions were separated. 
Western blots showed that the Fn3-49 Val22232Glu and 
Fn3-90 Gly27849Val variants significantly reduced the frag-
ment solubility compared to WT (Supplementary Fig. 12), 
mirroring the results observed when expressing the WT and 
variant single domains in bacteria.
Discussion
Following introduction of next generation sequencing into 
routine clinical diagnostics, TTN variants are increasingly 
identified in patients presenting with primary skeletal myo-
pathies. As TTN variants are not infrequent amongst con-
trol populations, information is needed regarding consistent 
clinico-pathological features that support the diagnosis of a 
TTN-related myopathy, and how to ascertain pathogenicity 
confidently, particularly with regards to TTN missense vari-
ants. In the present study focussing on patients presenting 
within the congenital myopathy (CM) spectrum, we provide 
further evidence for consistent clinical and pathological fea-
tures that support a diagnosis of a TTN-related myopathy. 
We also suggest a comprehensive approach to pathogenicity 
ascertainment of TTN genotypes involving missense vari-
ants, beyond the conventional tools of in silico analysis, via 
the biochemical and biophysical characterisation of domains 
containing missense variants.
On the clinical level, most patients presented with 
a severe CM, typically antenatally or from the neona-
tal period, and less frequently from infancy or later in 
childhood. Despite the early onset and often substantial 
motor developmental delay, and in contrast to some other 
severe CMs (for example, X-linked myotubular myopathy, 
XLMTM), more than two thirds of our patients achieved 
and maintained at least some degree of independent ambu-
lation, a remarkable observation also considering the unu-
sually long duration of follow-up in our cohort, with the 
oldest surviving patient currently 71-years-old. Despite 
the distinct genotypes, the patients compound heterozy-
gous for one truncating and one missense TTN mutation 
have a very similar phenotype to those with congenital 
titinopathies compound heterozygous for TTN truncating 
mutations [40]. Multiple contractures, spinal rigidity and 
scoliosis developed early in the disease course and were 
frequently progressive throughout life, resulting in clinical 
phenotypes resembling the King-Denborough syndrome 
(KDS) or Emery-Dreifuss muscular dystrophy (EDMD). 
Although the latter phenotype has been suggested as a 
distinct presentation of TTN-related myopathies [10], 
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in our experience there is a continuum of such features 
throughout the group of patients with TTN-related myopa-
thies. Another notable finding in our cohort was the high 
incidence of fractures that appeared out of proportion to 
the frequency of this feature in other CM, suggesting a 
more specific association. In contrast to all other major 
forms of CNM, extraocular muscle involvement was uni-
versally absent. Respiratory involvement was variable but 
necessitated constant respiratory support in around half 
of all patients. Cardiac involvement comprised congenital 
structural cardiac defects, acquired cardiomyopathies and 
arrhythmias, the latter occasionally preceding the develop-
ment of more definite cardiac dysfunction. Of note, care-
ful review of the family histories revealed not only une-
quivocally documented cardiomyopathies but also many 
unexplained cases of unexpected sudden cardiac death or 
heart problems attributed to lifestyle factors such as alco-
hol abuse, which considering our findings may have had a 
genetic contribution.
On the histopathological level, our findings consolidate 
TTN as a major cause of MmD [7] and CNM [6], but also 
emphasize that TTN-related CMs are most typically associ-
ated with a mixed rather than a “pure” histopathological 
picture, as noted in earlier studies [6, 7]. In contrast to other 
causes of CNM, in particular XLMTM due to mutations in 
MTM1 and DNM2, necklace fibres and radial strands were 
not typically observed.
Taken together, our findings suggest that a TTN-related 
myopathy should be strongly suspected in patients with 
clinical features of CM with variable cardiac but without 
extraocular muscle involvement, and a mixed histopathologi-
cal picture with cores and internalized nuclei as the most 
prominent feature.
Muscle imaging studies suggested a relatively consistent 
pattern of selective muscle involvement, with considerable 
overlap with that previously reported in other TTN-related 
myopathies such as TMD and HMERF. However, the pattern 
of selective muscle involvement did not show the consist-
ency seen in some other neuromuscular disorders (for exam-
ple, RYR1-related myopathies [26, 27]), and larger series 
will be required to confirm its specificity.
Depending on the location of the truncating TTN vari-
ants in differentially spliced exons, we are able to propose 
tentative genotype–phenotype correlations in particular with 
regards to the degree of cardiac involvement, which should 
help to inform counselling and health surveillance in indi-
vidual patients and their families.
Staining and Western blotting of patient tissue showed 
that C-terminal, M-band titin was present when only one 
allele harboured a truncating mutation (Fig. 3, Supplemen-
tary Fig. 1; patients 4, 22 and 24), suggesting the missense 
variant-containing allele is incorporated into the sarcomere, 
but absent when both alleles contained a truncating mutation 
(patient 29). The staining pattern for patient 29 suggests that 
at least the longer of the two truncating titin variants is fully 
integrated into the sarcomere, and there is therefore no evi-
dence of significant nonsense-mediated decay of the trun-
cated alleles. Ordered sarcomeres have been seen previously 
in patients with two splice site/truncating variants, albeit 
with disrupted I- and A-band regions [6].
At least eleven of our patients were compound heterozy-
gous for a TTN truncating and missense variant, as previ-
ously reported in other patients with TTN-related CNM [6]. 
A major emphasis of our study was the detailed functional 
and biophysical characterization of the TTN missense vari-
ants identified in our cohort, a particular diagnostic chal-
lenge in the ascertainment of TTN-related myopathies. Only 
one previously reported recessive TTN missense mutation 
in CM affecting the TK domain (Trp34072Arg) [7] has 
been analysed in detail, and was demonstrated to have a 
strongly destabilizing effect when expressed on a consti-
tutively-truncating background through disruption of the 
TK scaffolding function for autophagy adaptors Nbr1 and 
p62/SQSTM1. Although associated with a severe CM with 
cardiac involvement in the compound-heterozygous state, 
Trp34072Arg is also present in the general population, as 
expected for a recessive allele, highlighting an urgent unmet 
need for appropriate classification of recessive pathogenic 
TTN mutations [8]. It is particularly interesting that this vari-
ant was identified again in the unrelated patient 30 in the 
present study, co-inherited in trans with a truncating vari-
ant in a skeletal-muscle specific region. Accordingly, as the 
compound-heterozygous setting is only expressed in skeletal 
muscle, the patient shows no cardiac phenotype. We sug-
gest this unequivocally identifies the missense variant as a 
pathogenic recessive mutation whose phenotypic penetrance 
is governed by the position of the co-inherited pathogenic 
TTN variant.
We characterized several of the domains mutated in our 
patients in detail and compared those to similar TTN patho-
genic variants previously reported (in [8]), demonstrating a 
similar pattern supporting a disruptive effect of TTN mis-
sense mutations when expressed on a truncating background. 
Of note, we characterized the Val22232Glu mutation identi-
fied in Patient 4 in [7] (included as patient 22 in our series), 
affecting Fn3-49 and associated with MmD with additional 
internalized nuclei presenting from infancy, with a congeni-
tal ASD and a VSD, and a rapidly progressive cardiomyopa-
thy requiring cardiac transplantation at the age of 14 years. 
The variant domain is expressed insolubly in bacteria and 
remains unfolded following purification from the insoluble 
fraction. Despite its impact on domain folding, the allele 
expressing this variant is integrated into the sarcomere, and 
the variant is recessive with the parental carrier asympto-
matic. Similar to Fn3-49 Val22232Glu, 9 of the remaining 
11 variant domains were insolubly expressed in bacteria, and 
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Fn3-90 Gly27849Val and Fn3-120 Arg31847Pro could also 
not be refolded. Ig-1 Ala82Asp and Fn3-119 Pro31732Leu 
could be refolded, but were highly thermally destabilising, 
as were the solubly expressed Fn3-7 Trp16471Cys and Fn3-
20 Lue18237Pro variants. The mis-localisation of the con-
structs encompassing Fn3-49 Val22232Glu and Fn3-90 Gly-
27849Val transfected in cardiomyocytes and their reduction 
in solubility when expressed in HEK293 cells supports the 
notion that these mutations convey their pathogenic affects 
via destabilisation of their domain.
The impact of TMD/LGMD2J-linked mutations in Ig-169 
(M10) and HMERF-linked mutations in Fn3-119 have been 
attributed to misfolding and/or thermal destabilisation of 
the domains [24]. Alongside Fn3-119 Pro31732Leu, we 
have also purified Fn3-119 Cys31712Arg (Cys30071Arg in 
Hedberg et al. [24]), with 1D NMR spectroscopy confirm-
ing that these mutants can be refolded following insoluble 
expression (data not shown), in contrast to the Val22232Glu 
mutant in CM. The different pathways to disease between 
variants leading to domains that can or cannot be refolded 
seems crucial for understanding their pathomechanism and 
tissue specificity.
It is striking that structural “mirror images” of five of 
the twelve missense variants in our cohort have previously 
been linked to titinopathies. Analogous to Fn3-119 being 
a hotspot for HMERF-linked mutations, particular residue 
positions within titin domains may be hotspots for titinopa-
thies, at least in trans with truncating variants; this observa-
tion may be of importance for the interpretation of missense 
variants identified in future.
Intriguingly, the clinical phenotype of patients compound-
heterozygous for TTN truncating/missense variants is very 
similar to that found in patients carrying two recessive trun-
cating variants, raising the question how these recessive TTN 
variants impact on the titin protein in vivo [6]. Analogous 
to the TK Trp34072Arg mutation and the HMERF-linked 
mutations in Fn3-119, the impact of recessive disrupting TTN 
missense variants on proteostasis could be a key pathogenic 
feature of recessive titinopathies, a hypothesis supported by 
the observations of variant titin fragments co-localising with 
p62/SQSTM1 in C2C12 and HEK293 cells. We hypothesise 
that TTN missense variants can derail proteostasis by induc-
ing local cleavage or accelerated protein turnover, causing 
disintegration of titin (C-terminal fragments created by 
skeletal-muscle specific calpain-3 in TMD/LGMD2J [10]) 
or cleavage observed in some CM, or by directly impair-
ing the scaffolding functions of the M-band proteostasis hub 
[14]. Alterations to cellular proteostasis may be amenable to 
therapeutic intervention via stabilisation of the domains by 
chemical chaperones, inductors of endogenous chaperons or 
by promoting their accelerated degradation.
The present study offers clear strategies addressing the 
challenges of an accurate assessment of patients with 
suspected TTN-related myopathies, and emphasizes the 
need for a combined clinico-pathological, genetic and 
molecular approach to optimize diagnostic accuracy. Rare 
missense variants should be experimentally assessed at the 
protein domain level, with thermal destabilisation by more 
than approximately 15 degrees or complete misfolding/
unfolding of the expressed domain supporting a patho-
genic diagnosis for the variant when inherited in trans 
with a second TTN truncating or destabilising missense 
variant. These criteria should also prove helpful to assess 
the possible impact of suspicious missense variants in 
cardiomyopathies.
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